Luigi Montemurro, of Brigham and Women’s Hospital in Boston, met us at ERS 2019 in Madrid to discuss the recent trial of the fixed dose combination of atomoxetine and oxybutynin as the first successful pharmacotherapy for obstructive sleep apnoea.
1. Why is there not yet an effective pharmacotherapy for obstructive sleep apnoea (OSA)? (0:05)
2. What is the mechanism of action of the fixed dose combination of atomoxetine and oxybutynin (ato-oxy) in OSA? (1:16)
3. Could you tell us a little about the recent clinical trial of ato-oxy and its findings? (2:17)
4. What is the safety profile of this combination? (3:41)
5. What were the limitations of the study and what future studies are planned? (5:50)
Speaker disclosures: Luigi Taranto Montemurro is a consultant for Apnimed, Inc.
touchRESPIRATORY.com is an independent information resource supporting physicians, clinicians and leading industry professionals in continuously developing their knowledge, effectiveness and productivity, via free-to-access content in multimedia formats.
Filmed at the European Respiratory Society (ERS) International Congress 2019, Madrid, Spain.
Share this Video
Related Videos In Sleep Related Breathing Disorders
Margaret Pisani, CHEST 2022: Highlights and networking opportunities
CHEST 2022 took place between October 16-19 in Nashville, TN, we interviewed editorial board member Prof. Margaret Pisani (Yale School of Medicine. New Haven, CT, USA) around her personal congress highlights and the networking opportunities which were available on site. Questions What CHEST presentations had the greatest impact this year and what were your personal […]
John Harsh, CHEST 2022: Long term safety of FT218 in the treatment of narcolepsy
Once-nightly sodium oxybate (FT218) is currently being investigated in the open label phase 3 study RESTORE (NCT04451668) for the treatment of narcolepsy. We caught up with Prof. John Harsh (University of Colorado Boulder, Boulder, CO, USA) to discuss the aims, design, inclusion criteria and interim findings of the RESTORE study. The abstract ‘LONG-TERM SAFETY OF […]
Joerg Steier, ATS 2022: the Delphi Consensus Statements on Excessive Daytime Sleepiness in Obstructive Sleep Apnea
It was a pleasure to talk with Professor Joerg Steier (King’s College London, London, UK) around the development of the Delphi Consensus Statements on the diagnosis and management of excessive daytime sleepiness in obstructive sleep apnea and how these statements will help identify and address the unmet needs. The abstract ‘Development of Delphi Consensus Statements […]
Journal articles and more to your inbox
Get the latest clinical insights from touchRESPIRATORYSign me up!